re: Ann: HeartWare Completes Enrollment in De...
This is an axtract from their announcement from Feb 17th this year ---
Mr. Godshall added. “In our 450-patient destination therapy study, we concluded the year with 311 patients randomized and enrolled in the study. With 350 patients enrolled at the end of January, we remain on track to complete enrollment in the destination therapy study by mid-2012. Based on this momentum in the clinic and continued favorable feedback, we have increased investment related to U.S. launch readiness and for preparation to commence human clinical trials of our next generation platform, the MVAD® System, in 2012.”
Excellent that all patients for this trial are now enrolled 2 months before forecast. This is a rare event to be ahead of forecast dates in the medical field and to me indicates the resolve and application of the Heartware team.
We now have FDA approval approaching, DT trials fully enrolled and ahead of schedule, the Mvad trial commencement nearing and Dualis working on the wireless energy transfer system which will present a major development in the VAD market.
Despite the FDA's unreasonable delays l feel more confident with this stock as the months roll by. To me with such global uncertainty this type of stock offers a relatively safe haven compared with the wild fluctuations seen in many blue chip stocks.
Goes to show the worth of our analysts who have fairly well ignored this pearler!
HIN Price at posting:
$2.18 Sentiment: Buy Disclosure: Held
